EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Exelixis's enterprise value is $6,184 Mil.
Exelixis's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1,830 Mil. Therefore, Exelixis's EV-to-Revenue for today is 3.38.
The historical rank and industry rank for Exelixis's EV-to-Revenue or its related term are showing as below:
EXEL'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.21 Med: 7.69 Max: 50.88
Current: 3.37
During the past 13 years, the highest EV-to-Revenue of Exelixis was 50.88. The lowest was 2.21. And the median was 7.69.
EXEL's EV-to-Revenue is ranked better than 68.54% of 1033
companies
in the Biotechnology industry
Industry Median: 7.63
vs EXEL: 3.37
As of today (2024-04-25), Exelixis's stock price is $23.575.
Exelixis's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $5.70. Therefore, Exelixis's PS Ratio for today is 4.14.
Exelixis EV-to-Revenue Historical Data
The historical data trend for Exelixis's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Exelixis's EV-to-Revenue
For the Biotechnology subindustry, Exelixis's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exelixis's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exelixis's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Exelixis's EV-to-Revenue falls into.
Exelixis's current Enterprise Value is $6,184 Mil.
Exelixis's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,830 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exelixis's share price for today is $23.575.
Exelixis's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.70.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exelixis EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Exelixis's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EXEL has been successfully added to your 